About Express Scripts Holding Company (ESRX) — Dividend Analysis 2026
Express Scripts is a pharmacy benefit management (PBM) organization founded in 1986. It offers integrated services like pharmacy claims processing, home delivery, formulary management, specialty pharmacy via Accredo, and data-driven drug utilization insights. The company is a subsidiary of Cigna following a $54 billion acquisition completed in December 2018.
Is ESRX a good dividend investment in 2026?
ESRX offers a 2.17% forward yield with a 50% payout ratio. Strand Safety Score: 100/100 (Very Safe). The 5-year dividend CAGR of 0% is modest — investors should weigh current income against growth alternatives.
ESRX DRIP calculator — what's the difference?
With DRIP on a $10,000 investment over 10 years, your ESRX portfolio grows to $204.1K vs $194.5K without reinvestment. This is the compound interest effect in action.
ESRX dividend growth history & forecast
ESRX has grown its dividend by 0% over the last year and 0% annually over 5 years. At this pace, an investor who holds for 10+ years will see their yield on cost grow substantially above the current 2.17%.
Strand Safety Score™ is proprietary to DividendFlow. Inputs: FCF, Debt/EBITDA, Net Income from SEC filings via FMP. Not financial advice. N/A for ETFs, pre-revenue companies, and tickers without income statements.
🌍 ESRX Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold ESRX.
Gross yield
2.17%
Tax rate
15.00%
After-tax yield
1.84%
Real yield (−CPI)
-0.96%
Account/Country
Tax Rate
After-tax Yield
Real Yield
$10K Annual Income
🇺🇸 Roth IRA / 401k
0%
2.17%
-0.63%
$217 / yr
🇺🇸 US Taxable (15%) ✓
15%
1.84%
-0.96%
$184 / yr
🇺🇸 US Taxable (20%)
20%
1.74%
-1.06%
$174 / yr
🇬🇧 UK ISA
0%
2.17%
-0.63%
$217 / yr
🇬🇧 UK Taxable
8.75%
1.98%
-0.82%
$198 / yr
🇨🇦 TFSA
0%
2.17%
-0.63%
$217 / yr
🇨🇦 CA Taxable
25%
1.63%
-1.17%
$163 / yr
🇦🇺 Super (pension)
15%
1.84%
-0.96%
$184 / yr
🇦🇺 AU Taxable
30%
1.52%
-1.28%
$152 / yr
🇩🇪 DE Taxable
26.375%
1.60%
-1.20%
$160 / yr
🇫🇷 FR Taxable
30%
1.52%
-1.28%
$152 / yr
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 ESRX Income Goal & Break-Even
Dividend Break-Even
50yr+
Years for dividends to fully repay your ESRX investment of $92.33/share (🇺🇸 US Taxable (15%) · 15.00% tax)
$10K invested · 10 Years
Dividends earned (DRIP)
$1.9K
Lost to inflation (2.8% CPI)
−$2.5K
Real purchasing power gain
$-568.04
12-month CPI (US BLS via FMP economic-indicators).
How much do I need to invest in ESRX for:
Shares needed
14,118
Capital required
$1,303,515
Monthly income
$2,000
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 ESRX Dividend Payment Schedule
ESRX pays quarterly — 4 times per year. Next ex-div: TBD.
Jan
Feb
Mar
💰
Apr
May
Jun
💰
Jul
Aug
Sep
💰
Oct
Nov
Dec
💰
10 shares
$4.25 / payment
$17.00 / year after tax
100 shares
$42.50 / payment
$170.00 / year after tax
1,000 shares
$425.00 / payment
$1700.00 / year after tax
📊 ESRX vs Healthcare Benchmarks
How ESRX compares to typical Healthcare averages.
Benchmark: Healthcare
Dividend Yield▼-0.63% vs sectorBelow avg
ESRX
2.17%
avg
2.80%
5Y Dividend CAGR▼-6.80% vs sectorBelow avg
ESRX
0.00%
avg
6.80%
Payout Ratio▲-5.00% vs sectorBetter
ESRX
50.00%
avg
55.00%
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ESRX sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ ESRX Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
Insider
Title
Type
Date
Shares
Price
Total Value
Stettin Glen D.
officer: Sr. VP, Clin. Res. & New Sol.
D-Return
2018-12-20
31,678
$69.57
$2.20M
Stettin Glen D.
officer: Sr. VP, Clin. Res. & New Sol.
D-Return
2018-12-20
30,715
$67.62
$2.08M
Stettin Glen D.
officer: Sr. VP, Clin. Res. & New Sol.
D-Return
2018-12-20
1,500.572
—
—
Stettin Glen D.
officer: Sr. VP, Clin. Res. & New Sol.
D-Return
2018-12-20
27,234
$58.17
$1.58M
Stettin Glen D.
officer: Sr. VP, Clin. Res. & New Sol.
D-Return
2018-12-20
23,996
$77.15
$1.85M
Stettin Glen D.
officer: Sr. VP, Clin. Res. & New Sol.
D-Return
2018-12-20
45,009.331
—
—
Stettin Glen D.
officer: Sr. VP, Clin. Res. & New Sol.
D-Return
2018-12-20
24,019
$84.83
$2.04M
STERNBERG SEYMOUR
director
G-Gift
2018-03-12
453
—
—
STERNBERG SEYMOUR
director
G-Gift
2018-11-30
9,893
—
—
STERNBERG SEYMOUR
director
G-Gift
2018-12-12
9,892
—
—
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
🌍
Geographic Revenue Breakdown
Where ESRX earns its money
Foreign100%
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
📊 About This Data
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ESRX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →